Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phosphatidylcholine controlled release - Lipid Therapeutics

Drug Profile

Phosphatidylcholine controlled release - Lipid Therapeutics

Alternative Names: LT-02; Phosphatidyl choline; Retarded release phosphatidylcholine

Latest Information Update: 02 Jan 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Heidelberg
  • Developer Dr Falk Pharma; Lipid Therapeutics
  • Class Antiulcers; Cytoprotectives; Glycerophospholipids; Lipids
  • Mechanism of Action Mucoprotein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Ulcerative colitis

Most Recent Events

  • 02 Jan 2023 No development reported - Phase-III for Ulcerative colitis (Adjunctive treatment, Treatment-resistant) in Austria, Germany, Lithuania, Belgium, Netherlands, Hungary, Latvia, Poland, Slovakia (PO)
  • 18 Sep 2020 No recent reports of development identified for phase-III for Ulcerative colitis (Adjunctive treatment, Treatment-resistant) in USA, Czech Republic and Netherlands (PO) (NCT02849951)
  • 07 Feb 2017 Dr. Falk Pharma terminates a phase-III clinical trial due to IDMC recommendation in Ulcerative colitis (Treatment-resistant, Adjunctive treatment) in Austria, Belgium, the Czech Republic, Germany, Hungary, Latvia, Lithuania, Netherlands, Slovakia and Poland (PO) (NCT02142725)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top